TY - JOUR
T1 - Haptoglobin proved a prognostic biomarker in peripheral blood of patients with personalized peptide vaccinations for advanced castration-resistant prostate cancer
AU - Pang, Xiaoliang
AU - Tashiro, Kosuke
AU - Eguchi, Rieko
AU - Komatsu, Nobukazu
AU - Sasada, Tetsuro
AU - Itoh, Kyogo
AU - Kuhara, Satoru
N1 - Funding Information:
We are grateful to Dr. V. S. Chowdhury for critical reading of the manuscript. This study was supported by a grant from the Regional Innovation Cluster Program of the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
PY - 2013
Y1 - 2013
N2 - Haptoglobin (Hp) is a well-known acute-phase protein that possibly has influence on tumors through the immune response. This study was conducted to evaluate the correlation between Hp expression and the effect of treatment by cancer peptide vaccines in advanced castration-resistant prostate cancer (CRPC) patients. Hp expression was measured by RT-PCR using peripheral blood mononuclear cells (PBMCs) collected from advanced CRPC patients, who were divided into two groups: long-term survivors and short-term survivors. Before cancer peptide vaccination (pre-vaccination), Hp expression was almost same in the two groups, but after cancer peptide vaccination (post-vaccination), Hp expression was higher in short-term survivors, suggesting that Hp expression in the PBMCs increased in shortterm survivors after treatment by cancer peptide vaccines. Our results suggest that Hp expression level in the PBMCs can serve as a prognostic biomarker in treatment by cancer peptide vaccine in advanced CRPC patients.
AB - Haptoglobin (Hp) is a well-known acute-phase protein that possibly has influence on tumors through the immune response. This study was conducted to evaluate the correlation between Hp expression and the effect of treatment by cancer peptide vaccines in advanced castration-resistant prostate cancer (CRPC) patients. Hp expression was measured by RT-PCR using peripheral blood mononuclear cells (PBMCs) collected from advanced CRPC patients, who were divided into two groups: long-term survivors and short-term survivors. Before cancer peptide vaccination (pre-vaccination), Hp expression was almost same in the two groups, but after cancer peptide vaccination (post-vaccination), Hp expression was higher in short-term survivors, suggesting that Hp expression in the PBMCs increased in shortterm survivors after treatment by cancer peptide vaccines. Our results suggest that Hp expression level in the PBMCs can serve as a prognostic biomarker in treatment by cancer peptide vaccine in advanced CRPC patients.
UR - http://www.scopus.com/inward/record.url?scp=84878812823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878812823&partnerID=8YFLogxK
U2 - 10.1271/bbb.120893
DO - 10.1271/bbb.120893
M3 - Article
C2 - 23563546
AN - SCOPUS:84878812823
SN - 0916-8451
VL - 77
SP - 766
EP - 770
JO - Bioscience, Biotechnology and Biochemistry
JF - Bioscience, Biotechnology and Biochemistry
IS - 4
ER -
